trial · primary record
Epcoritamab
Diffuse Large B-cell Lymphoma
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 483 |
| Primary completion | 2028-04 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT04628494 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:56.254Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04628494
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- epcoritamab · compound